Novo Nordisk: FDA extends indication for Wegovy

(CercleFinance.com) - Danish pharmaceutical company Novo Nordisk has announced that the US FDA has extended the indication for its flagship drug Wegovy to reduce the risk of major adverse cardiovascular events (MACE).


This indication includes cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in overweight or obese adults with established cardiovascular disease.

This decision is based on the cardiovascular results of the SELECT trial, which demonstrated that Wegovy statistically significantly reduced the risk of MACE by 20% compared with placebo when added to standard treatment.


Copyright (c) 2024 CercleFinance.com. All rights reserved.